ALX Oncology Reveals Key Insights on CD47 Expression in Cancer Treatment
ALX Oncology Highlights CD47 in HER2+ Gastric Cancer Trials
ALX Oncology Holdings Inc. is set to present significant findings about CD47 expression at an upcoming conference dedicated to cancer immunotherapy. The company, known for its cutting-edge oncology solutions, has gathered data suggesting that CD47 overexpression may serve as a crucial predictive biomarker when using their leading candidate, evorpacept, to treat HER2+ gastric cancer.
Event Details for the Upcoming Presentation
This promising data will be showcased during the poster session at the Society for Immunotherapy of Cancer's (SITC) annual meeting happens shortly. Attendees can look forward to insights based on the Phase 2 ASPEN-06 study, which assessed evorpacept along with other established therapies in treating HER2-positive advanced gastric cancer, a condition notorious for its aggressiveness and limited treatment options.
What to Expect from the Presentation
The presentation, with the compelling title "CD47 expression as a predictive biomarker for evorpacept in HER2-positive gastric/gastroesophageal cancer from the Phase 2 randomized ASPEN-06 trial,” will be delivered by Dr. Zev A. Wainberg from the University of California, Los Angeles. Attendees will gain valuable insights on patient outcomes and the significance of CD47 as a biomarker in this specific cancer subtype.
Exploring the ASPEN-06 Trial
ASPEN-06 is an innovative study designed to evaluate the efficacy of evorpacept when combined with HERCEPTIN (trastuzumab), CYRAMZA (ramucirumab), and paclitaxel in treating patients with advanced gastric and gastroesophageal cancers. These patients have often seen their conditions progress despite previous treatments targeting HER2. In this multi-center trial, 127 participants took part, highlighting ALX Oncology's commitment to advancing treatment options in a challenging therapeutic landscape.
Why CD47 Matters
CD47, often referred to as a 'don't eat me' signal, plays a striking role in protecting cancer cells from immune system attack. By targeting CD47, ALX Oncology hopes to enhance treatment efficacy and patient outcomes, making strides towards safer and more effective cancer therapies. The focus on this biomarker aligns with broader trends in cancer treatment that emphasize personalized medicine and targeted therapies.
About ALX Oncology's Pipeline
The company's pipeline is filled with promising candidates designed to tackle various oncological challenges. Evorpacept has shown great potential and is currently undergoing extensive testing across numerous clinical trials. In addition to evorpacept, ALX Oncology is also developing ALX2004, an antibody-drug conjugate targeting EGFR, further diversifying their innovative treatments. The company is committed to turning the tide in cancer therapy, striving to extend life expectancy for patients with difficult-to-treat conditions.
Staying Connected with ALX Oncology
For those interested in the latest updates and developments from ALX Oncology, more information can be found on their official website and social media platforms. Their ongoing commitment to cancer research makes them a key player in the biotech landscape, actively seeking solutions that resonate with patient needs and medical advancements.
Frequently Asked Questions
What is the significance of CD47 expression in cancer treatment?
CD47 has been identified as a potential biomarker that may predict how well patients respond to certain cancer therapies, including evorpacept.
When and where will the presentation take place?
The presentation is scheduled for November 8 during the SITC 40th Annual Meeting, held at the Poster Hall in National Harbor.
How many patients were included in the ASPEN-06 study?
A total of 127 adult patients participated in the Phase 2 portion of the ASPEN-06 trial.
What therapies are being evaluated alongside evorpacept?
Evorpacept is being evaluated in combination with HERCEPTIN, CYRAMZA, and paclitaxel to assess their efficacy in treating advanced gastric cancer.
How can I learn more about ALX Oncology's progress?
You can visit ALX Oncology's website or follow them on social media platforms like LinkedIn for the latest news and updates on their clinical trials and initiatives.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.